Stock Markets May 24, 2026 11:42 PM

Jardine Matheson to acquire I-MED Radiology Network for A$3.4 billion as it expands into healthcare diagnostics

Hong Kong conglomerate will buy 100% of I-MED from Permira-advised funds and other shareholders; deal includes Harrison.ai stake and is expected to close in 2026 subject to approvals

By Derek Hwang

Jardine Matheson has agreed to purchase Australia-based I-MED Radiology Network for an enterprise value of A$3.4 billion ($2.4 billion). The Hong Kong group will acquire all shares from funds advised by Permira and other sellers, funding the transaction with a mix of cash reserves and debt. The deal includes I-MED’s minority holding in AI radiology developer Harrison.ai and is priced at about 11.5 times forecast adjusted EBITDA for the year ending June 2026, excluding the Harrison.ai stake. Regulatory approvals are required and closing is expected later in 2026.

Jardine Matheson to acquire I-MED Radiology Network for A$3.4 billion as it expands into healthcare diagnostics

Key Points

  • Jardine Matheson to buy 100% of I-MED Radiology Network for A$3.4 billion ($2.4 billion).
  • Deal includes I-MED’s minority stake in Harrison.ai and is valued at about 11.5 times forecast adjusted EBITDA for year ending June 2026, excluding Harrison.ai.
  • I-MED runs 215 imaging clinics in Australia and New Zealand, performs over 7 million procedures annually, and offers teleradiology in Australia, New Zealand and the U.S.

Jardine Matheson announced on Monday that it has entered into an agreement to buy I-MED Radiology Network, an Australian medical imaging provider, at an enterprise value of A$3.4 billion, equivalent to $2.4 billion. The Hong Kong-based conglomerate will acquire 100% of I-MED from funds advised by private equity firm Permira and from other shareholders.

The group said financing will come from its cash reserves and from debt facilities, but it did not provide a detailed breakdown of how much will be drawn from each source. Jardines also confirmed the purchase encompasses I-MED’s minority interest in Harrison.ai, a company that develops radiology artificial intelligence solutions.

Jardines framed the transaction as consistent with its strategy of investing for control in market-leading companies and moving into growth areas. In its announcement, the firm reported the transaction values I-MED at roughly 11.5 times forecast adjusted EBITDA for the year ending June 2026, with that multiple calculated excluding the Harrison.ai stake. EBITDA is earnings before interest, taxes, depreciation and amortisation.

The company said the acquisition is expected to be neutral to underlying earnings per share for Jardines in the first full year after closing and accretive thereafter.

"I-MED is already a market leader in radiology today, and we expect the business will expand further in I-MED’s core markets as well as new markets," Jardines’ CEO Lincoln Pan, who started in his role in December, said in the statement.

I-MED operates 215 diagnostic imaging clinics across Australia and New Zealand and conducts more than 7 million procedures annually, according to Jardines. The business also provides teleradiology services - the remote reading of medical scans - in Australia, New Zealand and the United States.

The transaction remains subject to regulatory approvals and is projected to close later in 2026, Jardines said. The announcement noted that Jardines completed its buyout of Mandarin Oriental in January.

Financial detail on the split between cash and debt financing was not disclosed. Jardines supplied the currency conversion used in its announcement: ($1 = 1.3970 Australian dollars).


Summary

Jardine Matheson will purchase I-MED Radiology Network for A$3.4 billion ($2.4 billion), acquiring all shares from Permira-advised funds and other shareholders. The deal, funded via a mix of cash and debt, includes I-MED’s minority stake in Harrison.ai and values the business at about 11.5 times forecast adjusted EBITDA for the year to June 2026, excluding the AI stake. The acquisition is expected to be neutral to Jardines’ underlying EPS in the first year post-close and accretive thereafter; regulatory approvals are required and closing is anticipated later in 2026.

Risks

  • Transaction requires regulatory approvals - potential for delay or additional conditions that could affect timing and terms (impacts healthcare and M&A activity).
  • Deal financing will come from a mix of cash reserves and debt without a disclosed split - potential balance sheet and funding implications for Jardines (impacts corporate finance and banking sectors).
  • Valuation multiple is calculated on forecast adjusted EBITDA excluding the Harrison.ai stake - sensitivity to forecast accuracy and treatment of the AI asset may affect valuation outcomes (impacts valuation and healthcare technology sectors).

More from Stock Markets

Toronto market ends at fresh record as healthcare, financials and materials lead gains Jun 4, 2026 After-Hours Movers: Lululemon Dips on Guidance as Software and Data Names Show Mixed Reactions Jun 4, 2026 Lululemon Lowers Fiscal 2026 Revenue and EPS Guidance as U.S. Demand Softens Jun 4, 2026 Anthropic Places Engineers Inside NSA to Support Mythos AI for Offensive Cyber Tasks Jun 4, 2026 Trump Directs $700M Toward Coal Industry, Lifting Peabody Shares Jun 4, 2026